Larger group testing
The next step is to carry out longer testing of the treatment in much larger groups of people (sometimes thousands) with the specific condition, compared against an existing treatment or a placebo to see which works better, while still checking side effects.
Interstitial lung diseases
- Zephyrus II: A phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of Pamrevlumab in subjects with Idiopathic Pulmonary Fibrosis:
- The purpose of this study is to test whether Pamrevlumab will slow down the progression of your lung disease, IPF. Pamrevlumab works by interfering with neutralising Connective Tissue Growth Factor (CTGF), a protein that the body normally produces. Studies have shown increased activity/levels of CTGF in IPF patients, which might be an important factor in the disease progression.
Breathing Matters Impact Report 2021
See how your donations have contributed to our groundbreaking research
Sign Up!
Receive our latest research updates and news